A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epogen®/Procrit® when given subcutaneously to patients with anemia and chronic kidney disease not yet on hemodialysis

Trial Profile

A phase III, randomized, open-label, active-controlled, multicenter, correction phase study of the efficacy, safety, pharmacokinetics, and pharmacodynamics of APO-EPO (epoetin alfa) as compared to Epogen®/Procrit® when given subcutaneously to patients with anemia and chronic kidney disease not yet on hemodialysis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Anaemia
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Apotex
  • Most Recent Events

    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top